ProteinLogic appoints Mr Damon Parkington as Assay Development & Research Scientist

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Damon Parkington as Assay Development and Research Scientist to provide technical leadership in the development of novel immunoassays for research and to bring expertise on relevant clinical instruments to further the company’s R&D and business development strategies.

Damon Parkington is an HCPC-registered Biomedical Scientist with a Clinical Biochemistry background. He has gained experience in a wide range of laboratory techniques whilst working in NHS Blood Sciences laboratories. His specialty is immunoassay development and he has extensive experience in this, having developed immunoassays using both manual and automated instruments.

Damon is “delighted to have been given the opportunity to apply the skills and experience I gained during my previous employment in NHS Blood Sciences laboratories to the field of biomarker discovery with ProteinLogic, it is a privilege to be a member of this impressive team. I am excited to be a part of the discovery process and look forward to seeing the company’s discoveries being transformed into a product that can be used in the field”.

ProteinLogic appoints Mr Mahesh Shah as Executive Chairman

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Mahesh Shah (MBA) as Executive Chairman to lead the business as it expands into the TB diagnostics space.
Mahesh Shah was the founder and CEO of the retail pharmacy business Nucare PLC, a company with operations in the UK as well as overseas. Under his stewardship the business grew both organically and through joint ventures and acquisitions, and he led a successful trade sale in 2007, realising an enterprise value of approximately £70 million.

Mr Shah has professional qualifications in pharmacy, accounting, finance and business, and has extensive practical expertise in international business. He has held board positions with a number of start-up companies, playing a significant role in strategy and commercial agreements.

He has been involved with ProteinLogic for over 5 years, in executive and non-executive roles, and in this time, amongst other achievements, he has successfully raised over £5m in funding and forged productive collaborations with academics, research scientists, clinicians and third party suppliers and contractors.

Mr Shah’s commercial expertise and professional knowledge of the healthcare sector will be a particular asset when it comes to developing ProteinLogic’s commercial offering. On agreeing his appointment, Mr Shah commented: “Having been a part of the PL family for some years, I am enthusiastic about the company’s potential and I look forward to augmenting its growth and steering it through any future challenges. I am delighted to have a talented and committed team around me as we pursue our commercial and technical ambitions.”

ProteinLogic awarded Horizon 2020 grant by the European Commission to develop novel cancer diagnostic tests

A European Consortium of leading academic and clinical partners, including ProteinLogic, a UK based biomarker discovery company, have been awarded a grant by the European Union Horizon 2020 SME program to help harness the diagnostic power of genome sequencing in day-to-day clinical practice.

ProteinLogic are pleased to announce they have been awarded €415,000 by the European Commission, for the development of a new cancer diagnostic test, comprising both genomic and proteomic biomarkers. The funding was awarded as a result of a successful €2.95 million grant application in partnership with five other European Clinical and Academic Collaborators.
The ability to sequence the complete genome holds great promise in the prevention and treatment of cancer. However, there are significant challenges in translating genome sequence information into clinical cancer practice. The goal of this project is to integrate genomic data with proteomic data to develop diagnostic tools for better risk assessment and early diagnosis of cancers. The combination of genomic data and proteomic data may also allow the prediction of response to drugs, disease burden, and likelihood of recurrence.

The three year €2.95 million project will expand and integrate ProteinLogic’s unique panel of biomarker proteins with genetic and epigenetic biomarkers selected from the very large public databases as well as biomarkers identified from clinical samples analysed under the program. The project also addresses the full chain of computational and statistical tools that are needed for clinically relevant diagnosis and intervention, including discovery in large cohorts, validation of putative causal sites in model systems and development of targeted cancer-risk panels. The project will deal with critical aspects of how data are collected, stored, organized, integrated, analysed and exploited in cancer genetic clinics. The project aims to provide a concerted, cross-disciplinary framework for better understanding, integration and use of cancer clinical data in the evaluation of the multitude of genetic variants and mutations involved in cancer susceptibility, for the direct benefit of cancer patients. The project will focus on breast cancer, colorectal cancer and stomach cancer.

The consortium brings together complementary expertise. It is led by Professor Angel Carracedo who is an international expert in the genetics of Mendelian and complex traits, including pharmacogenomics, as well as in population genetics; and heads the Foundation of Genomic Medicine of Galicia, Spain. Dr Xavier Estivill is the head of the Genomics and Personalized Medicine Unit, University Hospital Quirón Dexeus, Women’s Health Department, Spain. Dexeus is one of the largest private clinics in Europe that is exclusively devoted to women’s health. Dr Aura Carerra is the group leader of the Genotoxic and Stress Unit at the prestigious Curie Institute, France. The European Molecular Biology Laboratory has made many scientific breakthroughs and its London branch, the EMBL-EBI is a hub for bioinformatics research and services, developing and maintaining a large number of scientific databases. Dr Stephan Ossowski heads the Genomic and Epigenomic Variation in Disease group at the Centre for Genomic Regulation in Barcelona, an international biomedical Research Institute of Excellence.

ProteinLogic’s Chairman Mahesh Shah said: “We are delighted that the European Commission is funding this exciting collaboration of European experts in the field of cancer genomics. As the only commercial organisation in the consortium, we hope to contribute both ProteinLogic’s proprietary proteomic know-how as well as lead on any commercial opportunities that might arise from this project.”

ENDS

Further information:
Mahesh Shah, ProteinLogic Ltd, telephone: +44 (0) 203 178 2045 mahesh.shah@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

Horizon 2020

euflagHorizon 2020 is the financial instrument of the European Union, implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Horizon 2020 is the biggest ever EU research and innovation program. Through the SME Instrument, the European Union wants to finance the most innovative small companies with a high growth potential. The program promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
By coupling research and innovation, Horizon 2020 is helping to drive economic growth with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.
Selected SMEs, showing a strong ambition to develop, grow and internationalise, shall be supported across Horizon 2020 with a dedicated instrument to provide staged and seamless support covering the whole innovation cycle.

For more information please visit http://cordis.europa.eu/programme/rcn/664237_en.html

Consortium led by ProteinLogic awarded €3.58million grant by the EU Horizon 2020 SME Instrument to develop a rapid point-of-care TB test

ProteinLogic, a biomarker discovery company, and its collaborator, Biosensia, an in vitro diagnostic company have been awarded a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB).

rapiflex

Almost 9m new cases of TB occur annually and there are over 1.4m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated uptake of new tools and strategies for better diagnosis, treatment and prevention of all forms of TB. The ProteinLogic TB test will enable the rapid diagnosis of the active form of TB using a simple blood sample that can be taken and analysed at the point-of-care.

The three year €3.58million project will integrate ProteinLogic’s unique panel of biomarker proteins with Biosensia’s RapiPlex rapid diagnosis platform which can rapidly determine levels of multiple proteins in blood within 15-20 minutes and is suitable for use in a local community healthcare setting. The EU funding, under the dedicated instrument “Clinical research for the validation of biomarkers and/or diagnostic medical devices”, will be used to create a prototype device for rapid, point-of-care human TB diagnostics.

Infectious diseases (e.g. HIV/AIDS, tuberculosis and malaria), are a global concern, accounting for 41% of the 1.5 billion disability adjusted life years worldwide, with 8% of these in Europe.

The program is enhanced by the expertise of several global academic TB Groups who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic. These include Imperial College London, University College London, the University of Cape Town (UCT) in South Africa and the Foundation for Innovative New Diagnostics (FIND). Prof. Ajit Lalvani is Chair of Infectious Diseases, National Institute of Health Research Senior Investigator and Wellcome Senior Clinical Research Fellow at Imperial College London. Dr Marc Lipman is Senior Lecturer & Honorary Consultant Physician in Respiratory & HIV Medicine at the Royal Free Hospital, London and also Deputy Director of UCL-TB Centre. Prof Keertan Dheda is Professor of Respiratory Medicine and Head of the Lung Infection and Immunity Unit at University of Cape Town. FIND is a not-for-profit foundation whose aim is to provide innovative and affordable diagnostic products for all levels of the health care system in developing countries.

ProteinLogic’s Chairman Mahesh Shah said: “We are thrilled that the European Commission is funding this exciting collaboration, especially in light of the very high level of entries. The EU received 580 project proposals involving 785 SMEs and we are particularly pleased to have been selected after evaluation by independent experts. We are looking forward to working with our partners to develop a prototype device and accelerate the development of this innovation for the benefit of patients.”

ENDS

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline.

Horizon 2020

euflagHorizon 2020 is the financial instrument of the European Union, implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Horizon 2020 is the biggest ever EU research and innovation program. Through the SME Instrument, the European Union wants to finance the most innovative small companies with a high growth potential. The program promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

By coupling research and innovation, Horizon 2020 is helping to drive economic growth with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Selected SMEs, showing a strong ambition to develop, grow and internationalise, shall be supported across Horizon 2020 with a dedicated instrument to provide staged and seamless support covering the whole innovation cycle.

For more information please visit http://cordis.europa.eu/programme/rcn/664237_en.html

Consortium led by ProteinLogic awarded £1.2m grant by the UK’s innovation agency, the Technology Strategy Board, to develop a rapid point-of-care TB test

CAMBRIDGE, UK (2013-11-12) – ProteinLogic, a biomarker discovery and exploitation company, Microtest Diagnostics, an in vitro diagnostic protein multiplexing company, and its collaborators have been awarded a grant by the government-backed Technology Strategy Board – the UK’s national innovation agency – to help support the development of MICROLOGIC™, a rapid point-of-care test for tuberculosis (TB).

Almost 9m new cases of TB occur annually and there are over 1m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated uptake of new tools and strategies for better diagnosis, treatment and prevention of all forms of TB. The MICROLOGIC™ test will enable the rapid differentiation of the active and latent forms of TB using a simple blood sample that can be taken and analysed at the point-of-care.

The three year £1.8m project will integrate ProteinLogic’s unique panel of biomarker proteins with Microtest Diagnostic’s CE-marked rapid diagnostic platform which can rapidly determine levels of multiple proteins in blood within a few hours and is suitable for use in a local doctor’s office. The Technology Strategy Board funding will be used to create a prototype device for rapid, point-of-care human TB diagnostics.

The consortium has been enhanced by the expertise of various global academic TB Groups who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic. These include the London School of Hygiene & Tropical Medicine (LSHTM), the University of Sheffield and the University of Cape Town (UCT) in South Africa. Dr Ruth McNerney of LSHTM and Prof Keertan Dehda of UCT are members of the STOP TB Working Group on New Diagnostics and Dr McNerney chairs the subgroup on point-of-care tests. She is also an advisor to the UK All Party Parliamentary Group on TB.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are thrilled that the Technology Strategy Board is funding this exciting collaboration. We are

looking forward to working with our partners to develop a prototype device and accelerate the application of this innovation for the benefit of patients.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline including a novel test to stratify patients with chronic hepatitis B infection.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills, the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

ProteinLogic appoints Dr Aron Rachamim as Chief Operating Officer

CAMBRIDGE, UK (2013-06-21) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Aron Rachamim as Chief Operating Officer (COO) to provide technical and business leadership in the execution of the company’s R&D and business development strategies.

Aron graduated from the University of Oxford with an MPhys in Physics, following which he obtained an MPhil in Micro- & Nanotechnology Enterprise from the University of Cambridge. He then stayed on at Cambridge to study for a PhD in Engineering working on biosensors. Prior to joining ProteinLogic he founded a university spin-out company and practised as an independent management consultant. His combination of relevant technical and business experience will be a real asset to the Company.

ProteinLogic’s Chairman Dr Rodgers said: “We are delighted to welcome Aron to his new role at ProteinLogic. His appointment will strengthen the Company’s management team and increase our executive capacity. We look forward to working with him as he plays a significant role in the further development of the Company”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first two products in the pipeline are novel diagnostic blood tests for tuberculosis and hepatitis B virus infections. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.
www.proteinlogic.com

ProteinLogic wins Med Tech award at NHS Healthcare Innovation Expo 2013

CAMBRIDGE, UK (2013-03-25) – ProteinLogic, the biomarker discovery and exploitation company, was judged to have presented the strongest proposal in the Med Tech category to the Innovators’ Den at the NHS Healthcare Innovation Expo 2013 in London on March 14th.

ProteinLogic’s Chairman Dr Paul Rodgers presented the winning pitch to a panel including leading venture capitalists and senior NHS decision makers in front of a live audience. He outlined the ProteinLogic technology and its progress in implementing a business strategy to commercialise biomarker-based diagnostic tests for a range of diseases including tuberculosis and hepatitis B.

Eighty companies entered the competition and five were selected to present at the Innovators’ Den in each of three categories: Digital Innovations, Med Tech and Service Challenges. The competition was organised by the Technology Strategy Board and Capita.

Dr Rodgers said: “We are delighted with the recognition of ProteinLogic’s innovative technology and its business proposition provided by the distinguished panel of investors and NHS decision makers. We thank the Technology Strategy Board for giving us the opportunity to participate in the Innovators’ Den.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB and hepatitis B diagnostic tests there are a number of potential follow-on products in the Company’s pipeline.
www.proteinlogic.com

ProteinLogic awarded Technology Strategy Board funding to a novel diagnostic test for tuberculosis

CAMBRIDGE, UK (2013-02-18) – ProteinLogic awarded Technology Strategy Board funding to support its research into a novel diagnostic test for tuberculosis
ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new diagnostic test for tuberculosis (TB).

ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to differentiate between patients with active and latent TB infections. The Technology Strategy Board funding, awarded through the Biomedical Catalyst programme, will enable ProteinLogic to carry out clinical feasibility studies to optimise the test, and to provide proof of confidence before committing to an R&D programme to develop the test. The funding will also support market research to identify the optimum route to market, and to develop a commercialisation plan.

Existing TB diagnostic technology is globally acknowledged to be sub-optimal. This project aims to develop a new methodology for the diagnosis of active TB, and for differentiation from the latent form. Accurate, early diagnosis and treatment of TB reduces the prevalence of infective cases and has dramatic potential for disease control. Existing TB diagnostic methodologies are dependent on the isolation of the microorganism from clinical samples; this new diagnostic test utilises the profiling of the unique immunological response to TB infection to confirm the diagnosis.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are delighted that the Technology Strategy Board is funding this project. Their funding will allow us to continue to optimise our novel TB test and to develop a commercialisation plan. We thank the Technology Strategy Board for its support.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline including a novel test to stratify patients with chronic hepatitis B infection.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills, the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org
The funding was awarded by the Technology Strategy Board through the Biomedical Catalyst programme. The £180 million Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK.

ProteinLogic awarded Technology Strategy Board funding to a novel diagnostic test for Hepatitis B

CAMBRIDGE, UK (2012-09-03) – ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new Diagnostic Test for Hepatitis B.
ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to stratify patients with chronic hepatitis B infection. The Technology Strategy Board funding will enable ProteinLogic to undertake market research to establish whether there is a commercially viable market opportunity and to carry out a small clinical study to provide proof of confidence before committing to an R&D programme to develop the test.

A successful diagnostic test would enable personalised treatment of patients suffering from hepatitis B infection, leading to better clinical outcomes and better compliance. The NHS itself would be expected to benefit from significant savings as the expensive treatments would be targeted to patients that are most likely to have a sustainable response.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are delighted that the Technology Strategy Board is funding this project. Their funding will allow us to collaborate with Professor Graham Foster at Barts Health and Queen Mary University of London where he leads the Liver Unit’s research programme on clinical and scientific aspects of chronic viral hepatitis. We thank the Technology Strategy Board for its support”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

ProteinLogic’s development pipeline comprises 14 different ImmiPrint® signatures in disease areas including infectious, inflammatory, autoimmune, oncology and metabolic diseases. Following commercial analysis, the Company has identified a significant unmet need for a simple, rapid, and inexpensive blood test that is capable of diagnosing tuberculosis (TB). Early clinical studies indicate that the ImmiPrint® TB signature may be able to discriminate between active and latent forms of TB. The novel hepatitis B diagnostic test is one of a number of potential follow-on products in the Company’s pipeline.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

The funding was awarded by the Technology Strategy Board through its SBRI competition for development contracts “Stratified medicine: Determining patient response”. The competition has been developed in collaboration with the partners of the Technology Strategy Board’s Stratified Medicine Innovation Platform to address the key issue identified in the Stratified Medicine Technology Roadmap to incentivise uptake of new stratified medicine approaches within the UK healthcare system.

ProteinLogic appoints Dr. Berwyn Clarke as new Non-Executive Director

CAMBRIDGE, UK (2012-07-31) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Berwyn Clarke as a Non-Executive Director.  Dr Clarke joins the ProteinLogic Board with 25 years’ experience in diagnostics and pharmaceuticals working for start-ups and global businesses such as GlaxoWellcome and Bayer Diagnostics. He is Founder and Chief Scientific Officer of Lab21 Ltd, a rapidly growing healthcare diagnostics business, providing state-of-the-art diagnostic infectious disease products to blood-banks and clinical labs on a worldwide basis; molecular diagnostic products; and molecular diagnostic services in personalised medicine, mainly in oncology. Dr Clarke played a leading role in taking Lab21 from a start-up in 2005 to a significant global player in diagnostic products and services today with service operations in Europe and North America and sales into over 130 countries.

ProteinLogic’s Chairman Dr Paul Rodgers said: “I am delighted that Berwyn has joined the Board where his business and diagnostics industry expertise will help commercialisation of the Company’s ImmiPrint® biomarker technology. The Board believes that Berwyn’s skills, knowledge and expertise will help progress the Company’s development plans to the next stage.”

Dr Clarke said: “I am thrilled to be joining the Company at this exciting stage of its development and I am looking forward to working with the ProteinLogic team.

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has

developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

ProteinLogic’s development pipeline comprises 14 different ImmiPrint® signatures in disease areas including infectious, inflammatory, autoimmune, oncology and metabolic diseases. Following commercial analysis, the Company has identified a significant unmet need for a simple, rapid, and inexpensive blood test that is capable of diagnosing tuberculosis (TB). Early clinical studies indicate that the ImmiPrint® TB signature may be able to discriminate between active and latent forms of TB.

www.proteinlogic.com